Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Antengene Corporation Limited

Equities

6996

KYG039571008

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 11:05:11 2024-04-17 pm EDT 		5-day change 1st Jan Change
0.89 HKD 0.00% Intraday chart for Antengene Corporation Limited -8.25% -55.50%
Mar. 22 Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 20 Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Antengene Corporation Limited

Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List MT
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance CI
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States CI
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma CI
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day CI
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 CI
Antengene Unaware of Reasons Behind Recent Share Price Drop, Surge in Trade Volume MT
Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hansoh, Antengene Join Forces for Anti-Tumor Tablet Commercialization in China; Antengene Shares Rise 4% MT
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China CI
Hong Kong Regulator Gives Go Ahead to Antengene’s Application for Multiple Myeloma Drug MT
Antengene Says Hong Kong Approves Myeloma Drug MT
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma CI
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma CI
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers CI
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 CI
US FDA Clears Perform Trial for Antengene's Tumor Treatment MT
Antengene Announces Five Presentations At the 2023 American Association for Cancer Research Meeting CI
Antengene Corporation Limited Announces Board Changes CI
Antengene Shrinks Loss in 2022 as Revenue Jumps Nearly Sixfold MT
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Antengene Obtains China Approval for Phase I Study of Tumor Treatment MT
Antengene Corporation Limited Announces Approval for the Phase I Clinch Trial of ATG-022 CI

Chart Antengene Corporation Limited

Chart Antengene Corporation Limited
More charts

Company Profile

Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Sector
Biotechnology & Medical Research
Calendar
2024-08-15 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Antengene Corporation Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8227 CNY
Average target price
1.666 CNY
Spread / Average Target
+102.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANTENGENE CORPORATION LIMITED Stock Antengene Corporation Limited
-55.50% 76.7M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.39% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.61% 96.84B
ARGENX SE Stock argenx SE
-1.02% 21.48B
BIONTECH SE Stock BioNTech SE
-18.14% 20.82B
GENMAB A/S Stock Genmab A/S
-6.87% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.70% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.89% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.12% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.25% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. News Antengene Corporation Limited
  5. Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10%